Pharmicell (005690) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pharmicell (005690) has a cash flow conversion efficiency ratio of 0.080x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.78 Billion ≈ $5.95 Million USD) by net assets (₩110.43 Billion ≈ $74.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmicell - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Pharmicell's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Pharmicell total liabilities for a breakdown of total debt and financial obligations.
Pharmicell Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmicell ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Magic Software Enterprises Ltd
TA:MGIC
|
0.064x |
|
Wuhan Sanzhen Industry Holding Co Ltd
SHG:600168
|
-0.051x |
|
GH RESEARCH PLC DL-025
F:1KA
|
N/A |
|
Changzhou Galaxy Century Microelectronics Co Ltd
SHG:688689
|
0.006x |
|
Minerva S.A
SA:BEEF3
|
0.504x |
|
EuroTeleSites AG
F:7YF
|
N/A |
|
Sichuan Xichang Electric Power Co Ltd
SHG:600505
|
0.100x |
|
BETTER COLLECTIVE EO-01
F:9C8
|
0.020x |
Annual Cash Flow Conversion Efficiency for Pharmicell (2010–2024)
The table below shows the annual cash flow conversion efficiency of Pharmicell from 2010 to 2024. For the full company profile with market capitalisation and key ratios, see 005690 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩86.44 Billion ≈ $58.58 Million |
₩3.50 Billion ≈ $2.37 Million |
0.040x | -72.46% |
| 2023-12-31 | ₩80.40 Billion ≈ $54.48 Million |
₩11.81 Billion ≈ $8.01 Million |
0.147x | +42.35% |
| 2022-12-31 | ₩76.66 Billion ≈ $51.95 Million |
₩7.91 Billion ≈ $5.36 Million |
0.103x | +226.26% |
| 2021-12-31 | ₩63.87 Billion ≈ $43.28 Million |
₩-5.22 Billion ≈ $-3.54 Million |
-0.082x | -152.00% |
| 2020-12-31 | ₩57.11 Billion ≈ $38.70 Million |
₩8.98 Billion ≈ $6.08 Million |
0.157x | +10828.39% |
| 2019-12-31 | ₩51.52 Billion ≈ $34.91 Million |
₩-75.50 Million ≈ $-51.16K |
-0.001x | -102.04% |
| 2018-12-31 | ₩47.49 Billion ≈ $32.18 Million |
₩3.40 Billion ≈ $2.31 Million |
0.072x | +300.00% |
| 2017-12-31 | ₩55.99 Billion ≈ $37.95 Million |
₩-2.01 Billion ≈ $-1.36 Million |
-0.036x | -442.90% |
| 2016-12-31 | ₩94.60 Billion ≈ $64.11 Million |
₩988.97 Million ≈ $670.21K |
0.010x | +132.06% |
| 2013-12-31 | ₩82.42 Billion ≈ $55.86 Million |
₩-2.69 Billion ≈ $-1.82 Million |
-0.033x | +72.09% |
| 2012-12-31 | ₩101.58 Billion ≈ $68.84 Million |
₩-11.87 Billion ≈ $-8.04 Million |
-0.117x | +40.15% |
| 2011-12-31 | ₩82.82 Billion ≈ $56.13 Million |
₩-16.17 Billion ≈ $-10.96 Million |
-0.195x | +77.02% |
| 2010-12-31 | ₩9.90 Billion ≈ $6.71 Million |
₩-8.41 Billion ≈ $-5.70 Million |
-0.850x | -- |
About Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more